[{"ID":"33643_71_NCT02142829","TOPIC_YEAR":2021,"RESPONSE":"$}}%E2%80%8B%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%","PROBA":0.9997967011},{"ID":"6651_15_NCT00895089","TOPIC_YEAR":2021,"RESPONSE":"# A: eligible\nB: excluded\nC: not relevant for clinical trial\n\nThe patient is not eligible for the clinical trial because they have a history of CAD and are currently being treated for pyogenic liver abscess, which are both exclusion criteria for the trial. Additionally, the patient has a history of hyperlipemia, hypertension, and chronic kidney disease, which may be relevant to the study but are not explicitly listed as inclusion or exclusion criteria. Therefore, the patient is \"excluded\" from the clinical trial.","PROBA":0.9907034638},{"ID":"8196_12_NCT00935896","TOPIC_YEAR":2022,"RESPONSE":"#1: Yes, the patient is eligible for the clinical trial.\n#2: No, the patient is not eligible for the clinical trial.\n\nPlease select one of the above options based on the patient's condition and the inclusion\/exclusion criteria of the clinical trial.","PROBA":0.9991958631},{"ID":"16897_36_NCT00395135","TOPIC_YEAR":2021,"RESPONSE":"#1: Yes, the patient is eligible for the clinical trial.\n#2: No, the patient is not eligible for the clinical trial.\n#3: Not relevant for the clinical trial.\n\nPlease select one of the above options by typing the corresponding number.","PROBA":0.9855946101},{"ID":"10439_15_NCT04584866","TOPIC_YEAR":2022,"RESPONSE":"#1: The patient is not eligible for the clinical trial because they do not have any of the conditions listed in the exclusion criteria.\n\n#2: The patient is eligible for the clinical trial because they do not have any of the conditions listed in the exclusion criteria.\n\n#3: The patient is not eligible for the clinical trial because they have a condition listed in the exclusion criteria (DMD).\n\n#4: The patient is eligible for the clinical trial because they do not have any of the conditions listed in the exclusion criteria, and their condition (DMD) is not relevant to the study.","PROBA":0.9874614735},{"ID":"21376_30_NCT04145011","TOPIC_YEAR":2022,"RESPONSE":"# A 47-year-old woman with a history of osteoarthritis and pain in her knee is eligible for the clinical trial.\n\nB 47-year-old woman with a history of osteoarthritis and pain in her knee is not eligible for the clinical trial.\n\nC 47-year-old woman with a history of osteoarthritis and pain in her knee is eligible for the clinical trial, but only if she has tried all other treatment options and has failed to respond to them.\n\nD 47-year-old woman with a history of osteoarthritis and pain in her knee is eligible for the clinical trial, but only if she has not tried any other treatment options before.","PROBA":0.982549295},{"ID":"14084_30_NCT02315430","TOPIC_YEAR":2021,"RESPONSE":"#A: Eligible","PROBA":0.9956736267},{"ID":"21157_30_NCT02664896","TOPIC_YEAR":2022,"RESPONSE":"#1: Yes, the patient is eligible for the clinical trial.\n#2: No, the patient is not eligible for the clinical trial.\n#3: Not relevant for the clinical trial.\n\nPlease select one of the above options based on the patient's information and the inclusion\/exclusion criteria of the clinical trial.","PROBA":0.9926972186},{"ID":"6759_15_NCT01837342","TOPIC_YEAR":2021,"RESPONSE":"# A: eligible\n\nThe patient is eligible for the clinical trial because they meet the inclusion criteria and do not meet the exclusion criteria. The patient is over 60 years old, has a history of sigmoid diverticulitis, and has been treated with conservative management. The patient does not have any contraindications to surgery, and they are able to consent to participate in the trial.","PROBA":0.9809964963},{"ID":"20956_30_NCT01402011","TOPIC_YEAR":2022,"RESPONSE":"#1: A 47-year-old woman with pain in the calf and knee when she bends down, which limits her activity, and has a history of osteoarthritis, and uses nonsteroidal anti-inflammatory drugs (NSAIDs) for the past two years.\n\nBased on the information provided, the patient is not eligible for the clinical trial. The patient has a history of osteoarthritis, which is an exclusion criterion for the study. Additionally, the patient is currently using NSAIDs, which could interfere with the study's outcome measures.","PROBA":0.9670163141},{"ID":"17271_36_NCT03346421","TOPIC_YEAR":2021,"RESPONSE":"#1: Yes, the patient is eligible for the clinical trial.\n#2: No, the patient is not eligible for the clinical trial.\n\nPlease select one of the above options based on the patient's information and the inclusion\/exclusion criteria provided for the clinical trial.","PROBA":0.9893253647},{"ID":"20949_30_NCT01380015","TOPIC_YEAR":2022,"RESPONSE":"# A: eligible\n\nThe patient is eligible for the clinical trial because they meet the inclusion criteria and do not meet any of the exclusion criteria. The patient has osteoarthritis, which is the condition being studied in the clinical trial, and they are experiencing pain and swelling in their knee, which is a common symptom of osteoarthritis. The patient is also willing to consume a high rosmarinic acid spearmint tea, which is the intervention being tested in the clinical trial. Additionally, the patient does not have any of the exclusion criteria, such as other systemic or rheumatic arthritis, recent heart attack, stroke, cancer, or any other clinically significant medical condition that may interfere with the study.","PROBA":0.9897724892},{"ID":"33403_71_NCT00297154","TOPIC_YEAR":2021,"RESPONSE":"# A: eligible\nB: excluded\nC: not relevant for clinical trial\n\nPlease provide the final summary.","PROBA":0.9972070058},{"ID":"10145_15_NCT01826487","TOPIC_YEAR":2022,"RESPONSE":"#A: Eligible","PROBA":0.8859986626},{"ID":"5466_12_NCT03549052","TOPIC_YEAR":2021,"RESPONSE":"#1: Yes, the patient is eligible for the clinical trial.\n\nThe patient has Marfan's syndrome and severe mitral valve prolapse with regurgitation, which meets the inclusion criteria of the clinical trial. The patient is also symptomatic and prepared to undergo mitral valve repair\/replacement surgery, which aligns with the objective of the clinical trial to assess the outcomes of mitral valve replacement in patients with pulmonary hypertension.\n\nHowever, the patient's history of gestational diabetes mellitus, hypertension with pregnancy, and obesity may be considered as exclusion criteria, as they can affect the patient's overall health and increase the risk of complications during surgery. Nevertheless, these conditions do not necessarily preclude the patient from participating in the clinical trial.\n\nTherefore, based on the information provided, the patient is eligible for the clinical trial.","PROBA":0.9864913681},{"ID":"30608_65_NCT01552811","TOPIC_YEAR":2021,"RESPONSE":"#1: Yes, the patient is eligible for the clinical trial.\n#2: No, the patient is not eligible for the clinical trial.\n#3: Not relevant for the clinical trial.\n\nPlease select one of the above options by typing the corresponding number.","PROBA":0.9816925237},{"ID":"12542_27_NCT01724086","TOPIC_YEAR":2021,"RESPONSE":"#1: Based on the patient's history of chronic HCV infection and current treatment with IFN and RBV, the patient would be eligible for the clinical trial.\n\n#2: The patient's negative biopsy results for hepatocellular carcinoma and the absence of any evidence of liver cirrhosis or decompensated liver disease would also make the patient eligible for the clinical trial.\n\n#3: However, the patient's current treatment with direct antiviral drugs would exclude them from the clinical trial, as the study is only recruiting patients who have not received any HCV-specific direct antiviral agents.\n\nTherefore, the patient would be eligible for the clinical trial, but only if they discontinue their current treatment with direct antiviral drugs.","PROBA":0.9945915929},{"ID":"7703_17_NCT00256776","TOPIC_YEAR":2021,"RESPONSE":"#1: Yes, the patient is eligible for the clinical trial.\n#2: No, the patient is not eligible for the clinical trial.\n\nPlease select one of the above options based on the patient's information and the inclusion\/exclusion criteria of the clinical trial.","PROBA":0.9791400922},{"ID":"17224_36_NCT03066882","TOPIC_YEAR":2021,"RESPONSE":"#1: Yes, the patient is eligible for the clinical trial.\n#2: No, the patient is not eligible for the clinical trial.\n#3: Not relevant for the clinical trial.\n\nPlease select one of the above options by typing the corresponding number.","PROBA":0.9996163405},{"ID":"12356_27_NCT00157534","TOPIC_YEAR":2021,"RESPONSE":"# A 53-year-old man with chronic HCV infection for the past 2 years\n# He is on IFN (100 mg\/week) plus RBV (400 mg\/day) combination therapy for the past 9 months\n# Direct antiviral drugs were added to his treatment 6 months ago\n# His medical record shows previous positive HCV RNA tests as well as positive enzyme immunoassay for anti-HCV-antibodies\n# The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis\n\nBased on the information provided, the patient is eligible for the clinical trial.\n\nHere is the breakdown of the eligibility criteria:\n\nInclusion Criteria:\n\n* Chronic HCV infection (met)\n* Genotype 1 HCV infection (met)\n* Currently receiving or have received prior therapy with interferon (not met)\n\nExclusion Criteria:\n\n* Patients who did not respond or relapsed following therapy with interferon (not met)\n\nThe patient is eligible for the clinical trial because they are currently receiving combination therapy with IFN and RBV, and direct antiviral drugs were added to their treatment 6 months ago. The patient's recent biopsy was negative for hepatocellular carcinoma, and the only remarkable finding was chronic inflammation compatible with a chronic viral hepatitis.","PROBA":0.9912568908},{"ID":"10289_15_NCT03167255","TOPIC_YEAR":2022,"RESPONSE":"# A: eligible\n\nThe patient is eligible for the clinical trial because they meet the inclusion criteria and do not meet any of the exclusion criteria. The patient has been diagnosed with DMD and has completed Study NS-065\/NCNP-01-201, making them eligible for the extension study. The absence of dystrophin protein in the patient's muscle biopsy is also a criterion for inclusion in the study. None of the exclusion criteria, such as serious or severe adverse events, treatment for dystrophin or related protein induction, or participation in other investigational drug studies, are present in the patient's case. Therefore, the patient is eligible for the clinical trial.","PROBA":0.9868961023},{"ID":"6921_15_NCT03239262","TOPIC_YEAR":2021,"RESPONSE":"#1: A: Eligible\n\nThe patient is not eligible for the clinical trial because they do not meet the inclusion criteria of age between 40 and 80 years old. The patient is 70 years old, which is outside of the inclusion range. Additionally, the patient has a history of coronary artery disease, mitral valve prolapse, atrial fibrillation, hyperlipidemia, hypertension, chronic kidney disease, and hypothyroidism, which are all exclusion criteria for the trial.","PROBA":0.9569020969},{"ID":"21357_30_NCT04034394","TOPIC_YEAR":2022,"RESPONSE":"# A: eligible\nB: excluded\nC: not relevant for clinical trial\n\nPlease select one of the above options based on the patient's condition and the inclusion\/exclusion criteria of the clinical trial.","PROBA":0.9956477109},{"ID":"27939_40_NCT03585712","TOPIC_YEAR":2022,"RESPONSE":"#A: Eligible","PROBA":0.9630321115},{"ID":"6778_15_NCT01986686","TOPIC_YEAR":2021,"RESPONSE":"# A: eligible\n\nThe patient is eligible for the clinical trial because they have a history of Hinchey II diverticulitis, which is one of the inclusion criteria. Additionally, the patient does not have any of the exclusion criteria, such as prior episode of diverticulitis, right-sided diverticulitis, failure of recovery from first episode, cancer found at the site on screening colonoscopy, comorbidities prohibiting surgery, immunosuppressed patients, or Hinchey I, III, or IV diverticulitis. Therefore, the patient is eligible for the clinical trial.","PROBA":0.986519315},{"ID":"27956_40_NCT03696121","TOPIC_YEAR":2022,"RESPONSE":"# A: eligible\n\nThe patient is eligible for the clinical trial because they have prolonged oral bleeding after a tooth extraction, which meets the inclusion criteria of the trial. Additionally, the patient does not have any of the exclusion criteria, such as aneurysmal subarachnoid haemorrhage, haemorrhage suspected to be due to transformation of ischaemic stroke, or significant hypotension. Therefore, the patient is eligible to participate in the clinical trial.","PROBA":0.9951194581},{"ID":"21244_30_NCT03290807","TOPIC_YEAR":2022,"RESPONSE":"# The patient is eligible for the clinical trial.\n\nA 47-year-old woman with a history of osteoarthritis and current symptoms of pain in the calf and knee when bending, with normal vital signs and a small effusion in the right knee, would likely be considered eligible for the clinical trial. The patient's history of osteoarthritis and current symptoms align with the inclusion criteria of the trial, which is focused on patients with knee and\/or hip osteoarthritis. Additionally, the patient does not meet any of the exclusion criteria, such as having resolved osteoarthritis or other diseases in the joints. Therefore, the patient would likely be considered eligible for the clinical trial.","PROBA":0.9869432231},{"ID":"14063_30_NCT01994343","TOPIC_YEAR":2021,"RESPONSE":"$}}%E2%80%8B%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%","PROBA":0.9991939558},{"ID":"33635_71_NCT02087917","TOPIC_YEAR":2021,"RESPONSE":"# A: Eligible","PROBA":0.9938581809},{"ID":"14300_30_NCT04778865","TOPIC_YEAR":2021,"RESPONSE":"# A: eligible\n\nThe patient is eligible for the clinical trial because they have been diagnosed with Hashimoto's thyroiditis, which is one of the inclusion criteria, and they do not have any of the exclusion criteria. The patient is currently taking Levothyroxine, but this is not an exclusion criterion as long as the dosage has been stable for at least 4 weeks prior to screening. Additionally, the patient's BMI of 31 and history of weight gain do not preclude them from participating in the trial.","PROBA":0.9702930935},{"ID":"14291_30_NCT04658524","TOPIC_YEAR":2021,"RESPONSE":"#1: Yes, the patient is eligible for the clinical trial.\n#2: No, the patient is not eligible for the clinical trial.\n#3: Not relevant for the clinical trial.\n\nPlease select one of the above options based on the patient's information and the inclusion\/exclusion criteria of the clinical trial.","PROBA":0.979167697},{"ID":"7742_17_NCT00560352","TOPIC_YEAR":2021,"RESPONSE":"# A: eligible\n\nThe patient is eligible for the clinical trial because they meet the inclusion criteria and do not meet any of the exclusion criteria. The patient has multiple myeloma, which is the target disease for the clinical trial, and they have already been treated with melphalan and prednisone, which are the same or similar drugs being tested in the trial. Additionally, the patient has experienced a relapse of their myeloma, which makes them eligible for the trial. The patient's age, gender, and other medical conditions do not exclude them from participating in the trial.","PROBA":0.9852833124},{"ID":"30545_65_NCT01103284","TOPIC_YEAR":2021,"RESPONSE":"#1: Yes, the patient is eligible for the clinical trial.\n#2: No, the patient is not eligible for the clinical trial.\n#3: Not relevant for the clinical trial.\n\nPlease select one of the above options by typing the corresponding number.","PROBA":0.9923934643},{"ID":"10006_15_NCT00264888","TOPIC_YEAR":2022,"RESPONSE":"# A: eligible\n\nThe patient is eligible for the clinical trial because they have a diagnosis of Duchenne muscular dystrophy (DMD) and are between the ages of 5 and 18, which meets the inclusion criteria. Additionally, the patient does not have any of the exclusion criteria, such as a history of congestive cardiac failure, positive hepatitis B or C tests, low hemoglobin or albumin levels, abnormal liver function tests, or a history of solid organ or hematological transplantation. The patient is also not currently taking any other investigational drugs or immunosuppressive therapy, and has not been exposed to thiazolidinedione PPAR\u03b3 agonists within the past 28 days. Therefore, the patient is eligible to participate in the clinical trial.","PROBA":0.9908071761},{"ID":"12824_27_NCT04664894","TOPIC_YEAR":2021,"RESPONSE":"#1: Yes, the patient is eligible for the clinical trial.\n\nThe patient is a male with chronic HCV infection, which meets the inclusion criterion of being a male patient with chronic HCV infection. The patient is also 53 years old, which is within the age range of 18-75 years specified in the exclusion criterion. Additionally, the patient is already diagnosed with HCV and on DAAs therapy, which meets the exclusion criterion of patients already diagnosed with HCV and on DAAs therapy. Therefore, the patient is eligible for the clinical trial.","PROBA":0.9955798177},{"ID":"10258_15_NCT02814019","TOPIC_YEAR":2022,"RESPONSE":"#A: Eligible\n\nThe patient is eligible for the clinical trial because they meet the inclusion criteria and do not meet any of the exclusion criteria. The patient has been diagnosed with DMD, which is the condition being studied in the clinical trial, and they are taking glucocorticoid steroids, which is a requirement for participation in the study. The patient does not have any of the exclusion criteria, such as symptomatic heart failure or ongoing participation in another therapeutic trial, that would prevent them from being eligible for the study.","PROBA":0.9752017879},{"ID":"28019_40_NCT04095715","TOPIC_YEAR":2022,"RESPONSE":"#1: Yes, the patient is eligible for the clinical trial.\n\n#2: No, the patient is not eligible for the clinical trial.\n\n#3: Not relevant for the clinical trial.","PROBA":0.9803781279},{"ID":"8008_17_NCT03100877","TOPIC_YEAR":2021,"RESPONSE":"# A: eligible\n\nThe patient is eligible for the clinical trial because they have high-risk multiple myeloma, which is the condition being studied in the trial. The patient has already received melphalan and prednisone, which are included in the trial, and has also received thalidomide and velcade, which are not excluded. The patient has experienced a relapse of their myeloma, which is a common reason for patients to be included in clinical trials. The patient's age and other medical conditions do not appear to be exclusionary.","PROBA":0.9808057378},{"ID":"25336_36_NCT02603081","TOPIC_YEAR":2022,"RESPONSE":"# A: eligible\nB: excluded\nC: not relevant for clinical trial\n\nPlease provide the answer and explain why the patient is eligible or excluded based on the criteria provided in the clinical trial.","PROBA":0.9969998411},{"ID":"27551_40_NCT00816660","TOPIC_YEAR":2022,"RESPONSE":"# A: Eligible\n\nThe patient is eligible for the clinical trial because she has a diagnosis of type 3 von Willebrand disease and the study is specifically looking for patients with this condition. The patient's history of prolonged oral bleeding after a tooth extraction and her family history of excessive menstrual bleeding are also relevant to the study. Additionally, the patient does not have any of the exclusion criteria, such as a history of acquired or hereditary coagulation disorders, inhibitors, or other medical conditions that could make her ineligible for the study.","PROBA":0.9790970245},{"ID":"14113_30_NCT02644707","TOPIC_YEAR":2021,"RESPONSE":"#1: Based on the patient's history, the patient is eligible for the clinical trial.\n\n#2: Based on the patient's history, the patient is not eligible for the clinical trial.\n\n#3: Based on the patient's history, the patient is not sure if they are eligible for the clinical trial.\n\nPlease select one of the above options.","PROBA":0.9684338276},{"ID":"16980_36_NCT01026584","TOPIC_YEAR":2021,"RESPONSE":"# Aripiprazole # Clinical Trial # Efficacy # Safety # First Episode Psychosis # DSM-IV # Substance Abuse # Dependence # Medical Illness # Pregnant # Lactating # Women # Contraception","PROBA":0.972821566},{"ID":"25320_36_NCT02494687","TOPIC_YEAR":2022,"RESPONSE":"#1: Yes, the patient is eligible for the clinical trial.\n#2: No, the patient is not eligible for the clinical trial.\n#3: Not relevant for the clinical trial.\n\nPlease select one of the above options based on the patient's condition and the inclusion\/exclusion criteria of the clinical trial.","PROBA":0.9871388659},{"ID":"30811_65_NCT02893306","TOPIC_YEAR":2021,"RESPONSE":"# A: eligible\n\nThe patient is eligible for the clinical trial because they have type 1 diabetes, which is the condition being studied, and they do not have any of the exclusion criteria listed (pregnancy, significant comorbidities, HIV, HBV, HCV, HTLV-1, HLTV-2, or VDRL positive).","PROBA":0.9926514689},{"ID":"25109_36_NCT00789061","TOPIC_YEAR":2022,"RESPONSE":"#1: Yes, the patient is eligible for the clinical trial.\n\n#2: No, the patient is not eligible for the clinical trial.\n\nPlease select one of the above options by typing '1' or '2'.","PROBA":0.9893636317},{"ID":"25568_36_NCT04331015","TOPIC_YEAR":2022,"RESPONSE":"$}}%EOF\n\n---\n\nHello! Based on the information provided, the patient is not eligible for the clinical trial. The patient's symptoms of dizziness, nausea, and ringing in the ear do not align with the study's focus on DFNA9, and the patient does not have the required c.151C>T, p.Pro51Ser variant. Additionally, the patient's age is outside of the specified range of 18-65 years.\n\nHowever, if the patient's symptoms persist or worsen, it may be worth considering other clinical trials or treatment options that are more relevant to their condition.\n\nPlease let me know if you have any further questions or concerns.","PROBA":0.97091491},{"ID":"27734_40_NCT02264730","TOPIC_YEAR":2022,"RESPONSE":"# Patient is eligible for the clinical trial\n\nThe patient is eligible for the clinical trial because the trial is focused on evaluating the effectiveness of ClotFoam as an adjunct to hemostasis in abdominal surgery, and the patient has a condition that requires abdominal surgery (tooth extraction) and is experiencing excessive bleeding. The patient's age and gender are not exclusion criteria for the trial, and the patient does not have any other medical conditions that would preclude participation. Therefore, the patient is eligible for the clinical trial.","PROBA":0.9879130921},{"ID":"5246_12_NCT00456963","TOPIC_YEAR":2021,"RESPONSE":"# A: eligible\nB: excluded\nC: not relevant for clinical trial\n\nPlease provide a clear and concise answer.","PROBA":0.9851014343},{"ID":"27891_40_NCT03263923","TOPIC_YEAR":2022,"RESPONSE":"# A 23-year-old female with prolonged oral bleeding after tooth extraction\n# Has heavy menstrual cycles each month\n# No other medical problems\n# Takes no medications\n# Mother and grandmother have a history of excessive bleeding during menstrual periods\n# Normal platelet count and abnormal ristocetin cofactor assay, as well as CB <= 0.30 IU\/mL and FVIII:C <= 0.40 IU\/mL\n\nBased on the information provided, the patient is not eligible for the clinical trial because the trial is only for grandmothers living with their grandchildren, and the patient is not a grandmother. Additionally, the patient's medical condition is not related to the focus of the clinical trial, which is on the stress of caregiving.","PROBA":0.986417685},{"ID":"6852_15_NCT02607527","TOPIC_YEAR":2021,"RESPONSE":"# A: Eligible\nB: Excluded\nC: Not relevant for clinical trial\n\nPlease provide the final summary.","PROBA":0.9934024533}]
